Walleye Capital’s Axsome Therapeutics AXSM Stock Holding History

Walleye Capital’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,400	Closed	-$256K	–	4384
2025 Q4	$256K	Buy	1,400 +500	+56%	+$69.8K	﹤0.01%	3408
2025 Q3	$109K	Sell	900 -4,800	-84%	-$541K	﹤0.01%	3668
2025 Q2	$595K	Buy	5,700 +3,500	+159%	+$371K	﹤0.01%	2491
2025 Q1	$257K	Buy	2,200 +1,700	+340%	+$194K	﹤0.01%	3075
2024 Q4	$42.3K	Sell	500 -700	-58%	-$64.4K	﹤0.01%	4392
2024 Q3	$108K	Sell	1,200 -500	-29%	-$43.6K	﹤0.01%	4370
2024 Q2	$137K	Sell	1,700 -6,100	-78%	-$452K	﹤0.01%	4547
2024 Q1	$622K	Buy	7,800 +6,600	+550%	+$554K	﹤0.01%	3008
2023 Q4	$95.5K	Sell	1,200 -4,000	-77%	-$267K	﹤0.01%	4059
2023 Q3	$363K	Buy	5,200 +400	+8%	+$29.9K	﹤0.01%	3071
2023 Q2	$345K	Buy	+4,800	New	+$354K	﹤0.01%	2695
2023 Q1	–	Sell	-11,600	Closed	-$895K	–	3932
2022 Q4	$895K	Buy	11,600 +8,100	+231%	+$484K	0.02%	1066
2022 Q3	$156K	Buy	+3,500	New	+$175K	﹤0.01%	2240

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Capital's AXSM Position: Q1 2026 in Review

Walleye Capital reduced its Axsome Therapeutics (AXSM) stake by 42% in Q1 2026, selling an estimated $4.31M and leaving 35,119 shares worth $5.94M. The position accounts for 0.02% of the portfolio, ranked #701.

Walleye Capital first reported a position in AXSM in Q3 2018 and has held it in 13 quarters since. The position peaked at $17.6M in Q4 2019. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Walleye Capital held 35,119 shares of Axsome Therapeutics worth $5.94M as of Q1 2026.
Walleye Capital sold 24,981 Axsome Therapeutics shares in Q1 2026, an estimated $4.31M.
Axsome Therapeutics made up 0.02% of Walleye Capital's portfolio in Q1 2026, its #701 holding.
Walleye Capital first reported a position in Axsome Therapeutics in Q3 2018 and has held it in 13 quarters since.
Walleye Capital's Axsome Therapeutics position peaked at $17.6M in Q4 2019.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.